Introduction {#Sec1}
============

Severe pulmonary arterial hypertension (PAH) is associated with poor prognosis. The development of PAH induces hypertrophy of the right ventricle (RV) that often transition into RV failure. Heart failure of the right ventricle during chronic PAH is the most common cause of mortality in severe PAH, with metabolic and energetic derangements as a prominent signature of heart failure \[[@CR1]\]. In the hypertrophied and failing heart, the increased systolic wall stress in the ventricular wall would be expected to increase the energy demand, whereas the increased size of the cardiomyocyte and the decreased capillary density is anticipated to diminish the oxygen supply. These observations have led to the suggestion that there is an imbalance between oxygen/energy supply-demand in the hypertrophied heart, which possibly contributes to the transition to the decompensated, failing heart \[[@CR2]\]. The often observed decreased PCr/ATP ratio, increased reliance on glucose metabolism and elevated lactate levels \[[@CR3],[@CR4]\] are in support of such a mismatch, and suggest that the failing heart is an engine out of fuel \[[@CR5]\]. One possible cause for reduced ATP production in the failing heart could be the lack of enough oxygen provided to the mitochondria. Hitherto, this question has only been indirectly evaluated through ^1^H NMR techniques which estimate the ratio of deoxygenated to oxygenated myoglobin. Examining several heart failure models using this technique it was concluded that reduced oxygen availability does not play a role in heart failure \[[@CR3],[@CR6],[@CR7]\]. The sensitivity of this technique, however, is such that a signal can only be detected when the entire myocardial tissue investigated reaches an intracellular PO~2~ \< 20 mmHg \[[@CR3]\]. Since the mean PO~2~ at the level of the mitochondria in intact healthy heart is approximately 35 mmHg \[[@CR8]\], the myoglobin technique can only detect large decreases (\>40%) in myocardial oxygenation. Thus, relatively smaller decreases or any increase in myocardial oxygenation will go unnoticed with the ^1^H NMR technique. In addition, the mitoPO~2~ within the heart is highly heterogeneous, such that at a mean mitoPO~2~ of 35 mmHg a significant portion of mitochondria may have a mitoPO~2~ \< 20 mmHg \[[@CR8]\]. These mitochondria may become oxygen-limited, as studies in isolated mitochondria have demonstrated decreased oxygen consumption when PO~2~ drops down in the 10-20 mmHg range \[[@CR9],[@CR10]\].

Alternatively, ATP production could also diminish due to intrinsic mitochondrial remodelling resulting in suppression of mitochondrial energy production. Suppression of mitochondrial energy metabolism through mitochondrial metabolic reprogamming together with increased glycolysis was recently proposed as intrinsic mechanism in the development of heart failure \[[@CR11]\]. In addition, mitochondrial oxygen consumption may also be inhibited through competition of increased levels of NO with O~2~ at the level of cytochrome c oxidase during hypertrophy and heart failure \[[@CR12]\]. Irrespective of the precise mechanism, suppression of mitochondrial energy metabolism should be reflected by elevated mitoPO~2~. Therefore, the non-invasive determination of oxygenation within the intact heart may shed light on the important question whether the development of cardiac hypertrophy and the subsequent transition to heart failure is associated with increased hypoxia or suppressed mitochondrial energy production. Since mitochondria are the principal sites of ATP generation, they are the ideal site of determining the prevailing oxygen tension. Our group recently developed a non-invasive technique which allows, for the first time, the quantitative determination of the distribution of mitochondrial PO~2~ within the heart \[[@CR8],[@CR13]-[@CR15]\]. Validation studies in several cell lines have demonstrated that the delayed fluorescence signal and its lifetime is determined by mitochondrial PpIX and the amount of mitochondrial oxygen present \[[@CR15]\]. Subsequent studies, extending from cells to isolated organs to the *in vivo* organ for liver \[[@CR14]\] and heart \[[@CR8]\], validated that the lifetime of the specific delayed fluorescence signal measured in all these conditions did indeed reflect the mitochondrial oxygen tension*.* In the current project we now apply this novel technique to examine the *in vivo* mitochondrial oxygenation in the right ventricle during the development of cardiac hypertrophy and failure due to pulmonary arterial hypertension.

Methods {#Sec2}
=======

The experiments of this study were approved by the ethical committee for animal subjects of the Academic Medical Center at the University of Amsterdam and Erasmus Medical Center at the University of Rotterdam. Care and handling of the animals were in accordance with the guidelines for Institutional and Animal Care and Use Committees. Male Wistar rats (n = 22; 7-8 wk, 180-220 g, Harlan, Netherlands) were attributed to either receive an intraperitoneal injection of monocrotaline (MCT) at a dose of 30 mg/kg (n = 7) or 60 mg/kg (n = 9), or normal saline (n = 6). Body weight was monitored for the next 28 days.

Animal preparation {#Sec3}
------------------

Invasive measurements were performed on 28 days after intraperitoneal injection. We selected 28 days post MCT administration, because in our hands RV heart failure and sharp reductions in body weight then starts to develop before most of the animals die. Premedication was done with subcutaneous buprenorphine (Temgesic, Schering-Plough, Netherlands; 0.05 mg/kg), 30 minutes before intraperitoneal injection of NaOH-buffered 5-aminolevulinic acid (ALA; 200 mg/kg). ALA was administered to increase mitochondrial PpIX concentration. 30 minutes before instrumentation of the animals a further equal dose of buprenorphine was administered. Anesthesia was induced by isoflurane. 5% isoflurane in oxygen was used for controls, and 3% isoflurane for monocrotaline treated animals (pilot experiments showed increased sensitivity of MCT animals to isoflurane induction). Anesthesia was then similarly maintained for all groups by pentobarbital at 60 mg/kg initial dose followed hourly by 60% of the initial dose. Body temperature was rectally measured and kept at 37 ± 0.5°C with a heating pad. The airway was secured by tracheal intubation following which the animals were ventilated in pressure-controlled mode at 40% oxygen with a positive end-expiratory pressure of 2.5 mbar. The ventilator settings were checked by capnography and blood gases. The carotid artery and jugular vein were cannulated for blood pressure and heart rate monitoring and infusion of fluid (Ringer's lactate at 10 ml/kg/h) and drugs, respectively. A median upper laparotomy was performed, the diaphragm incised and the pericardium opened. The fiber optic probe for mitoPO~2~ measurements was positioned transdiaphragmally at approximately 1 mm from the right ventricle (RV) of the beating heart.

Experimental protocol {#Sec4}
---------------------

The measurements of the mitochondrial oxygen partial pressures (mitoPO~2~) were started at 2 hours after ALA injection, to allow sufficient increases in mitochondrial PpIX for the delayed fluorescence measurements. The experimental protocol consisted in the measurement of mitoPO~2~ at varying inspiratory oxygen fraction (40%, 30%, 21%, 40%) and at two dosages of dobutamine (Centrafarm, Etten-Leur, Netherlands), 2.5 μg/kg/min and 5 μg/kg/min. All measurements during the infusion of dobutamine were made at an inspiratory oxygen fraction of 40%. The 30 and 40% FiO2 are necessary to prevent non-physiological low arterial oxygen tension in the MCT animals, probably because in these animals the lung damage impaired ventilation/perfusion matching within the lungs. Every step of the protocol was maintained for 10 minutes before any measurement was performed. At each step 0.2 ml blood was sampled from the cannulated carotid artery and analyzed with a blood gas analyzer (ABL800 flex, Radiometer, Copenhagen). At the end of the experiment, right ventricular pressure was measured by transmyocardial puncture using a 23 gauge needle connected to a pressure transducer and automatic flushing system. After termination of the experiment, heart and lungs were excised and weighed. The heart was subsequently dissected into right and left ventricle, after a small apical part of the heart was removed for histological and biochemical processing. The tissue was immediately frozen in liquid nitrogen and stored at -80°C.

Mitochondrial PO2 measurements {#Sec5}
------------------------------

The principle and setup for *in vivo* mitoPO~2~ measurements was previously reported \[[@CR8],[@CR14],[@CR15]\], and a detailed description of the used setup was recently published \[[@CR13]\]. In brief, mitochondrial oxygen tension is measured with the Protoporphyrin IX (PpIX) -- Triplet State Lifetime technique. Application of ALA results in the mitochondrial accumulation of PpIX. PpIX displays oxygen-dependent quenching of delayed fluorescence lifetime. Mitochondrial PpIX is excited at 510 nm through an excitation fiber coupled to a tunable laser, and delayed fluorescence at 630-700 nm is detected by an emission fiber connected to a gated microchannel plate photomultiplier. A PC-based data-acquisition system sampled the signal at 1 MHz and averaged 64 laser pulses (repetition rate 20 Hz) prior to analysis. The delayed fluorescence signal was then used to recover the different mitoPO~2~ histograms from fitting the signal by a sum of rectangular distributions of delayed fluorescence lifetimes. Three separate series of 64 pulses were analyzed and averaged at each experimental condition.

Tissue analysis {#Sec6}
---------------

Three sections of the apex, 5 μm thick, were cut in a cryostat, collected on slides, fixed in 4% formaldehyde, stained with hematoxylin and eosin, dehydrated and mounted in Entellan (Merck). Images were obtained with a 40x objective, and cross-sectional area of individual myocytes was determined at the level of the nucleus using Image J ([imagej.nih.gov/ij/](http://www.imagej.nih.gov/ij/)), taking the pixel to aspect ratio into account \[[@CR16]\]. Within each section the cross-sectional area was determined for 6-12 cardiomyocytes. RV and LV homogenates were obtained by grinding the frozen tissue into powder in liquid nitrogen, dissolving the powder in 1 ml ice-cold homogenization buffer (0.5% Triton X-100, 250 mM sucrose, 20 mM Hepes (pH 7.4), 10 mM KCl, 1.5 mM MgCl~2~, 1 mM EDTA, 1 mM dithiothreitol, 0.1 mM PMSF, 5 μg/ml leupeptin and aprotinin and 1 μg/ml pepstatin), 15 min incubation, sonication and finally 1 min 10,000 g centrifugation to obtain the supernatant. Citrate synthase activity, as marker of mitochondrial content, and hexokinase and lactate dehydrogenase activities, as markers of glycolysis, were determined in the supernatant according to published spectrophotometric techniques \[[@CR17],[@CR18]\], and normalised to protein content (Bradford technique).

Statistics {#Sec7}
----------

The data are presented as mean ± SEM. One way analysis was performed followed by Fisher's probable least-significant-difference post hoc analysis between groups (SPSS Statistics 20). A value of P \< 0.05 was considered statistically significant.

Results {#Sec8}
=======

General characterization of MCT animals {#Sec9}
---------------------------------------

Two 60 mg/kg MCT animals (MCT60) died before 4 wk. One 30 mg/kg (MCT30) and one MCT60 animal died at induction of anesthesia. 6 animals of each MCT group completed the experimental protocol. Body weight developed to a similar degree for all three groups up to 3 wk. Thereafter the MCT60 group started to lose weight, such that at 4 wk body weight was significantly reduced for the MCT60 group as compared to control and MCT30 (Figure [1](#Fig1){ref-type="fig"}A). In addition, MCT60 demonstrated increased lung weight at 4 wk (Figure [1](#Fig1){ref-type="fig"}B). RV hypertrophy was similar in both MCT groups (Figure [1](#Fig1){ref-type="fig"}C and D), whereas peak RV pressure almost tripled in MCT60 rats (Figure [1](#Fig1){ref-type="fig"}E). These data indicate compensated RV hypertrophy for the MCT30 group, and the start of right heart failure for the MCT60 group.Figure 1**Body weight and anatomical and functional characteristics of right ventricle of control and MCT treated animals. A**. body weight after 28 d following MCT administration. **B-D**. lung mass, right ventricle (RV) mass relative over left ventricle (LV) mass, and cross sectional area (CSA) of cardiomyocytes in RV and LV, respectively, at end of 28 d following MCT treatment. **E**. systolic RV pressure measured at end experimental protocol (n = 6 per group).

Hemodynamics and blood oxygenation {#Sec10}
----------------------------------

Physiology of the animals during the experimental protocol is depicted in Figure [2](#Fig2){ref-type="fig"}. Although there was a trend that MCT in general lowers hemodynamics in the anesthetized animals, this only reached significance for heart rates (Figure [2](#Fig2){ref-type="fig"}A) during the dobutamine infusions; no significant depression of MAP (Figure [2](#Fig2){ref-type="fig"}B) was observed following MCT treatment. Reducing FiO~2~ was paralleled with reductions in arterial PO~2~ for both control and MCT animals, whereas arterial PO~2~ was in most conditions significantly higher for control versus MCT animals (Figure [2](#Fig2){ref-type="fig"}C). At 30% FiO~2~ the arterial oxygen tension was still at a normal physiological level (\~100 mmHg) for the MCT60 group, whereas at 21% FiO~2~ arterial oxygen tension dropped below normal arterial oxygenation levels (\<70 mmHg), indicating that at least 30% FiO~2~ was necessary to maintain physiological PaO~2~ in the MCT60 animals. There also was a non-significant trend for decreased oxygen saturation of hemoglobin in MCT animals at 21% FiO~2~ (Figure [2](#Fig2){ref-type="fig"}D).Figure 2**Hemodynamics (A: heart rate; B: mean arterial pressure (MAP)) and blood oxygenation (C: arterial oxygen tension; D: oxygen saturation of haemoglobin(Hb)) during the changes in inspiration oxygen (FiO** ~**2**~ **) and the administration of two dobutamine infusion rates.** \* p \< 0.05 relative to CON (control). (n = 6 per group).

Mitochondrial oxygen tension {#Sec11}
----------------------------

FiO~2~-dependent PpIX delayed fluorescence signals were obtained *in vivo* from the RV of control and MCT animals and the distribution of mitoPO~2~ histograms determined (Figure [3](#Fig3){ref-type="fig"}). At 40% FiO~2~, the distribution of mitoPO~2~ showed a rightward shift towards higher values for the MCT60 RV as compared to control RV (Figure [3](#Fig3){ref-type="fig"}A). The fraction of mitochondria with PO~2~ values below 20 mm Hg, assumed to be oxygen limited, was similar between control (54 ± 11%) and the MCT30 group (48 ± 12). However, significant less mitochondria within the RV of the MCT60 group (15 ± 10%) were observed in this low oxygen range as compared to control (Figure [3](#Fig3){ref-type="fig"}B). A similar pattern exists when F~i~O~2~ was reduced to 30% oxygen (Figures [3](#Fig3){ref-type="fig"}C-D). Only when inspired oxygen supply was further reduced to 21%, the fraction of mitochondria within the 0-20 mmHg PO~2~ range of the RV MCT60 group (42 ± 13%) increased to values similar as control (53 ± 5%) (Figure [3](#Fig3){ref-type="fig"}E-F). Resetting F~i~O~2~ again to 40% restored oxygenation to the initial 40% inspiration conditions, indicating reversibility of the phenomenon (Figures [3](#Fig3){ref-type="fig"}G-H).Figure 3**Right ventricle mitoPO** ~**2**~ **measurements during changes in inspiration oxygen content (FiO** ~**2**~ **) for control (CON) and monocrotaline-treated animals (MCT). A**, **C**, **E**, and **G**: total distribution of mitoPO~2~ during the different FiO~2~ settings. **B**, **D**, **F**, and **H**: the fraction of mitochondria displaying a mitoPO~2~ \< 20 mmHg during the different FiO~2~ settings. \* p \< 0.05 relative to CON (control). (n = 6 per group).

We next analyzed the responses of RV oxygenation towards increases in energy demand by using two different doses of dobutamine infusions (Figure [4](#Fig4){ref-type="fig"}). At a dobutamine dose of 2.5 μg/kg/min the differences observed in oxygenation between MCT60 and control RV persisted (Figure [4](#Fig4){ref-type="fig"}A-B); only at the highest dobutamine dose did the fraction of mitochondria in the 0-20 mmHg range in the MCT RV (32 ± 16%) become similar to that in control RV (49 ± 10%) (Figure [4](#Fig4){ref-type="fig"}C-D).Figure 4**Right ventricle mitoPO** ~**2**~ **measurements during administration of two doses of dobutamine (dobu) for control (CON) and monocrotaline-treated animals (MCT). A**, **C**. total distribution of mitoPO~2~ within RV. **B**, **D**. the fraction of mitochondria displaying a mito PO~2~ \< 20 mmHg. \*p \< 0.05 relative to CON (control). (n = 6 per group)".

Post-experimental metabolic analysis {#Sec12}
------------------------------------

Finally, we examined metabolic changes within RV and LV at the different stages of pulmonary hypertension (Figure [5](#Fig5){ref-type="fig"}). Citrate synthase activity was unaffected by MCT treatment in RV and LV, indicating similar mitochondrial mass among groups. Hexokinase (HK) activity was increased in the RV of both MCT groups. No change in HK activity was observed in LV. In contrast, lactate dehydrogenase (LDH) activity was only increased in the RV of the MCT30 group, but not in the RV of the MCT60 group. LDH activity in LV was unaltered (Figure [5](#Fig5){ref-type="fig"}). These data indicated a differential response of glycolytic enzymes to the development of RV failure.Figure 5**Metabolic marker enzyme activities in RV and LV of control and MCT treated animals 28 d following MCT administration. A**. citrate synthase (CS) as mitochondrial marker; **B**. hexokinase (HK) as glycolytic marker; **C**. lactate dehydrogenase (LDH), as lactate metabolism marker. \*p \< 0.05 relative to the respective CON (control). (n = 6 per group).

Discussion {#Sec13}
==========

Hypoxia at the level of the cardiomyocyte mitochondria is hypothesized as an important contributing factor in the development of cardiac failure \[[@CR2],[@CR5],[@CR19],[@CR20]\]. A critical evaluation of this hypothesis has been missing due to the lack of a technique enabling quantitative measurements of mitochondrial oxygenation within the *in vivo* working heart. In the present study, through application of a recently developed technique by our group, we show that at the initiation of cardiac failure, mitochondrial oxygenation is higher (under baseline conditions) or equal (under decreased oxygen supply or increased work demand conditions) as compared to healthy hearts. No decreased cardiac mitochondrial oxygenation was observed, arguing against hypoxia being an important contributor to the development of right heart failure.

Mitochondrial oxygenation and cardiac metabolic signature of RV failure {#Sec14}
-----------------------------------------------------------------------

Our observation of less mitochondria with low oxygen in the RV failure developing animals, suggests decreased mitochondrial oxygen consumption in the transition from compensated hypertrophy towards cardiac failure. Decreased oxygen consumption has indeed been directly measured 4-6 wk after MCT administration, although not in intact hearts but in permeabilized cardiac fibers or minced heart tissue \[[@CR19]-[@CR21]\]. Suppression of mitochondrial metabolism together with increased glycolysis was recently proposed as intrinsic mechanism underlying the development of pulmonary arterial hypertension and heart failure \[[@CR11]\]. This data would suggest that impairments in energy production (ATP synthesis) in RV heart failure, as reported by different groups \[[@CR19],[@CR22]\], are mainly metabolically mediated, and not through impairment of oxygen delivery. Theoretically, mitoPO~2~ can also be elevated as a consequence of increases in oxygen supply when going from the hypertrophied to the failing condition. However, such evidence cannot be found in literature. On the contrary, capillary density or coronary blood flow or angiogenesis are commonly decreased in hypertrophy or with the transition towards heart failing \[[@CR11],[@CR16],[@CR23]\]. The increased mitochondrial PO~2~ measured in this study is also not a result from a decrease in mitochondrial capacity, since citrate synthase activities were similar between control and MCT RV. Previous work from our group also demonstrated unaltered mitochondrial capacity in RV of MCT-treated animals \[[@CR16],[@CR24]\]. We did find elevated HK activities in the hypertrophied and failing RV, consistent with other studies \[[@CR25]-[@CR27]\]. Interestingly, increases in hexokinase were recently also noted as metabolic hallmark of a right heart failure program \[[@CR28]\]. The increase in HK is probably an adaptive mechanism, attenuating structural and maladaptive remodelling with pressure-overload \[[@CR29]\]. Interestingly, LDH activity was only increased in the compensated hypertrophied RV, but not in the failing RV. Thus, decreased number of mitochondria with low oxygen tension and loss of LDH increase are the specific metabolic markers observed in the present study that sets the developing failing RV apart from the compensated hypertrophied RV. Although increased cardiac HK has been associated with decreased cardiac oxygen consumption \[[@CR29]-[@CR31]\], or decreased LDH may decrease oxygen consumption considering lactate as important substrate for the heart \[[@CR32],[@CR33]\], further in-depth studies directed at these metabolic hypotheses are needed before any affirmative statements can be made. Alternatively, although not examined in the present study, mitochondrial oxygen consumption may also decrease due to cytochrome c oxidase inhibition by NO, which levels were shown to be increased in congestive heart failure \[[@CR12],[@CR34]\]. Irrespective of the exact molecular mechanism, our novel observation of higher *in vivo* mitochondrial oxygenation suggests impaired *in vivo* mitochondrial metabolism as a possible trigger for the development of RV failure.

In the current work the chemical substance MCT was used to induce pulmonary hypertension; however, pulmonary hypertension can have several different etiologies (chronic thromboembolic, pre-versus postcapillary pulmonary hypertension, connective tissue disease, etc.). Although we anticipate that, independent of the etiology, any increase in pulmonary arterial pressure will increase RV afterload and thereby most likely start the metabolic, mitochondrial, remodelling phase as described here for the MCT model, further research is warranted to state this more definitively for different pulmonary hypertension etiologies.

Methodological considerations {#Sec15}
-----------------------------

Under baseline conditions the animals were mechanically ventilated with 30-40% inspiration oxygen, which is above the ambient air content of oxygen (21%) with spontaneously breathing. The higher inspiration oxygen levels are necessary to compensate for the known ventilation-perfusion defects caused by anesthesia and mechanical ventilation in especially diseased humans and animals \[[@CR35],[@CR36]\] and are the recommended inspiration oxygen levels with mechanical ventilation used in the clinical arena. Mechanical ventilation in our healthy animals with a FiO~2~ of 21% resulted in an arterial tension of approximately 80 mmHg, below the 100 mmHg normally obtained with spontaneous breathing, indicating that the use of ambient air oxygen levels with mechanical ventilation and anesthesia is indeed associated with insufficient blood oxygenation. In addition, we needed at least a FiO~2~ of 30% to obtain a physiological normal arterial tension of 100 mmHg in the MCT60 animals. Most importantly, even with the *lower* arterial oxygen tension of the MCT60 animals as compared to healthy controls at 30% or 40% FiO~2~, there were still *less* mitochondria with pO~2~ \< 20 mmHg in the MCT60 RV, illustrating that the fewer mitochondria with low oxygen are not simple a result of higher arterial oxygen in these sick animals.

The present study used the monocrotaline-induced pulmonary arterial hypertension intervention as a model to study RV hypertrophy and failure. Because almost all animal models are not fully mimicking the clinical features of human pathologies, studies in different models of heart failure, e.g. infarction- or aortic constriction-induced models, will need to be examined to more definitely establish whether increased mitochondrial oxygenation is in general a signature of HF. In addition, although we did not fully characterise RV function with e.g. echocardiography, other studies demonstrated RV dysfunction with 60 mg/kg MCT at 3-6 weeks after MCT administration \[[@CR11],[@CR19],[@CR20],[@CR37],[@CR38]\]. Together with the reported decreased body weight and increased mortality in the present study it is likely that the MCT60 animals at 4 wk after MCT administration are in the critical transition phase of RV decompensation. However, the use of full RV function characterization with mitoPO~2~ measurements is needed in future studies to describe in more detail the relation between RV dysfunction and RV mitochondrial oxygenation.

Gianmarco M Balestra and Egbert G Mik contributed equally to this work.

**Competing interest**

EG Mik is founder and shareholder of Photonics Healthcare B.V., a company aimed at making the delayed fluorescence lifetime technology available to a broad public. Photonics Healthcare B.V. holds the exclusive licenses to several patents regarding this technology, filed and owned by the Academic Medical Center in Amsterdam and the Erasmus Medical Center in Rotterdam, the Netherlands. All other authors declare that they have no competing interest.

**Authors' contributions**

GMB designed studies, performed experiments, analysed data, and prepared and reviewed the manuscript. EGM designed studies, analysed data, and prepared and reviewed the manuscript, OE performed experiments, analysed data, and prepared and reviewed the manuscript, PACS performed experiments, analysed data, WJvd L designed studies, analysed data, and prepared and reviewed the manuscript. CJZ designed studies, performed experiments, analysed data, and prepared and reviewed the manuscript. All authors read and approved the final manuscript.
